HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Committed To Advancing Its Regulatory Science Capacity

This article was originally published in The Rose Sheet

Executive Summary

FDA cites "advances in the application of nanotechnology" among scientific "breakthroughs" that are revolutionizing the health-care community's ability to treat disease, making the notion of personalized care a reality and demanding more FDA involvement

You may also be interested in...



FDA Budget Issues Creep Into Strategic Priorities

“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says. Agency officials included stewardship, such as doing more with less funding, among the cross-cutting strategic priorities in its draft strategic priorities document for 2014-2018.

FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan

FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.

FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan

FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.

Related Content

UsernamePublicRestriction

Register

RS017271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel